Company research
Praxis Precision Medicines, Inc.
CIK 1689548Updated Sep 27, 2026
SecurityPRAX · NASDAQ · equity
PRAX price & chart
Loading TradingView…
NASDAQ:PRAX on TradingView ↗In the news
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Other Events
Items 8.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
Other Events
Items 8.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 937,907,000Source | 483,110,000Source | 87,948,000Source | 115,128,000Source |
| Property, Plant and Equipment, NetUSD | 147,000Source | 230,000Source | 588,000Source | 971,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 357,329,000Source | 215,372,000Source | 81,300,000Source | 61,615,000Source |
| Assets, CurrentUSD | 610,911,000Source | 404,372,000Source | 84,880,000Source | 110,840,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 11,580,000Source | 11,805,000Source | 3,580,000Source | 10,351,000Source |
| Operating Lease, Right-of-Use AssetUSD | 92,000Source | 1,131,000Source | 2,064,000Source | 2,901,000Source |
| Other Assets, NoncurrentUSD | 0Source | 416,000Source | 416,000Source | 416,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 59,771,000Source | 37,660,000Source | 18,279,000Source | 39,022,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 15,000Source | 14,000Source | 13,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 2,017,566,000Source | 1,281,522,000Source | 723,577,000Source | 606,918,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,140,008,000Source | -836,740,000Source | -653,921,000Source | -530,644,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 563,000Source | 654,000Source | 0Source | -173,000Source |
| Stockholders' Equity Attributable to ParentUSD | 878,136,000Source | 445,450,000Source | 69,669,000Source | 76,106,000Source |
| Liabilities and EquityUSD | 937,907,000Source | 483,110,000Source | 87,948,000Source | 115,128,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 59,771,000Source | 37,550,000Source | 15,749,000Source | 34,345,000Source |
| Operating Lease, Liability, CurrentUSD | 110,000Source | 1,259,000Source | 1,126,000Source | 1,005,000Source |
| Accounts Payable, CurrentUSD | 24,628,000Source | 12,528,000Source | 5,815,000Source | 14,672,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 110,000Source | 1,369,000Source | 2,495,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 35,033,000Source | 23,763,000Source | 7,416,000Source | 15,850,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 926,100,000Source | 469,500,000Source | 81,300,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 33,941,000Source | 41,360,000Source | 24,857,000Source | 28,593,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 12,097,000Source | 6,713,000Source | -8,855,000Source | 3,892,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -249,068,000Source | -131,757,000Source | -111,136,000Source | -185,043,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -311,148,000Source | -248,494,000Source | 38,950,000Source | 96,889,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 56,000Source | 0Source | 50,000Source | 444,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 2,089,000Source | 308,000Source | 137,000Source | 260,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 702,173,000Source | 514,323,000Source | 91,871,000Source | 10,465,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 141,957,000Source | 134,072,000Source | 19,685,000Source | -77,689,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 357,745,000Source | 215,788,000Source | 81,716,000Source | 62,031,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 224,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 33,941,000Source | 41,360,000Source | 24,857,000Source | 28,593,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 926,100,000Source | 469,500,000Source | 81,300,000Source | — |
| DepreciationUSD | 140,000Source | 358,000Source | 432,000Source | 419,000Source |
| Gain (Loss) on InvestmentsUSD | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | 59,083,000Source | 56,305,000Source | 42,054,000Source | 59,946,000Source |
| Income Tax Expense (Benefit)USD | 471,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -303,268,000Source | -182,819,000Source | -123,277,000Source | -214,029,000Source |
| Nonoperating Income (Expense)USD | 22,930,000Source | 17,346,000Source | 3,096,000Source | 957,000Source |
| Operating ExpensesUSD | 326,198,000Source | 208,718,000Source | 128,820,000Source | 214,986,000Source |
| Other Nonoperating Income (Expense)USD | 22,930,000Source | 17,346,000Source | 3,096,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 1,426,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 8,553,000Source | 2,447,000Source | — |
| Operating Income (Loss)USD | -326,198,000Source | -200,165,000Source | -126,373,000Source | -214,986,000Source |
| Other Nonoperating Income (Expense)USD | 22,930,000Source | 17,346,000Source | 3,096,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -302,797,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 471,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -303,268,000Source | -182,819,000Source | -123,277,000Source | -214,029,000Source |
| Earnings Per Share, BasicUSD per share | -13.48Source | -10.21Source | -18.69Source | -4.64Source |
| Earnings Per Share, DilutedUSD per share | -13.48Source | -10.21Source | -18.69Source | -4.64Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 22,504,676Source | 17,906,794Source | 6,594,316Source | 46,096,737Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 22,504,676Source | 17,906,794Source | 6,594,316Source | 46,096,737Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 471,000Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | 59,083,000Source | 56,305,000Source | 42,054,000Source | 59,946,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -302,839,000Source | — | — | — |
| Interest Income, OtherUSD | — | — | — | 957,000Source |
| Nonoperating Income (Expense)USD | 22,930,000Source | 17,346,000Source | 3,096,000Source | 957,000Source |
| Operating ExpensesUSD | 326,198,000Source | 208,718,000Source | 128,820,000Source | 214,986,000Source |
| Research and Development ExpenseUSD | 267,115,000Source | 152,413,000Source | 86,766,000Source | 155,040,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | 1,000,000Source |
Filing attachments
tm2528989d1_ex4-1.htm · 8-K · 2025-10-20
EX-4.1 3 tm2528989d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 PRAXIS PRECISION MEDICINES, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: October 20, 2025 Praxis Precision Medicines, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entit…
Read attachment ↗